Stifel Nicolaus Lowers Nyxoah (NASDAQ:NYXH) Price Target to $19.00

Nyxoah (NASDAQ:NYXH) had its price target reduced by Stifel Nicolaus from $27.00 to $19.00 in a research report released on Monday, Benzinga reports. Stifel Nicolaus currently has a buy rating on the stock.

NYXH has been the subject of several other research reports. HC Wainwright dropped their price target on Nyxoah from $22.00 to $18.00 and set a buy rating for the company in a research note on Friday, May 24th. Oppenheimer dropped their price target on Nyxoah from $20.00 to $15.00 and set an outperform rating for the company in a research note on Wednesday, May 15th. Piper Sandler lifted their price target on Nyxoah from $15.00 to $20.00 and gave the stock an overweight rating in a research note on Wednesday, March 6th. Finally, Cantor Fitzgerald dropped their price target on Nyxoah from $18.00 to $17.00 and set an overweight rating for the company in a research note on Wednesday, May 15th. One research analyst has rated the stock with a hold rating and five have assigned a buy rating to the stock. Based on data from MarketBeat.com, Nyxoah presently has a consensus rating of Moderate Buy and an average target price of $17.80.

Nyxoah Trading Down 13.6 %

NASDAQ:NYXH opened at $6.87 on Monday. Nyxoah has a 52-week low of $4.00 and a 52-week high of $20.00. The stock has a fifty day moving average of $9.24 and a 200 day moving average of $9.83. The company has a debt-to-equity ratio of 0.13, a current ratio of 3.94 and a quick ratio of 3.70.

Nyxoah (NASDAQ:NYXH) last issued its quarterly earnings results on Tuesday, May 14th. The company reported ($0.45) earnings per share (EPS) for the quarter, hitting the consensus estimate of ($0.45). Nyxoah had a negative return on equity of 42.14% and a negative net margin of 843.49%. The firm had revenue of $1.33 million during the quarter, compared to analyst estimates of $1.20 million. On average, equities analysts forecast that Nyxoah will post -1.72 EPS for the current fiscal year.

Institutional Inflows and Outflows

A hedge fund recently bought a new stake in Nyxoah stock. Ikarian Capital LLC purchased a new stake in shares of Nyxoah S.A. (NASDAQ:NYXH) in the first quarter, according to the company in its most recent disclosure with the SEC. The institutional investor purchased 50,699 shares of the company’s stock, valued at approximately $684,000.

About Nyxoah

Nyxoah SA, a medical technology company, focuses on the development and commercialization of solutions to treat sleep disordered breathing conditions. The company's lead solution comprises Genio system, a CE-Marked, patient-centric, and hypoglossal neurostimulation therapy to treat moderate to severe obstructive sleep apnea.